Juvenil Miyastenia Gravis
Özet
uvenil Miyastenia Gravis (JMG), 18 yaş altı çocuklarda nöromüsküler iletimin otoantikorlarca bloke edilmesi sonucu gelişen, kaslarda dalgalı güçsüzlük ve yorgunlukla karakterize nadir bir otoimmün hastalıktır. Patofizyolojisinde asetilkolin reseptörleri (AChR), MuSK veya LRP4 gibi yapılara karşı üretilen antikorlar temel rol oynarken, klinik tablo oküler tutulumdan solunum krizlerine kadar geniş bir yelpazede seyreder. Tanı, klinik bulgular ve spesifik serolojik testlerin yanı sıra elektrofizyolojik yöntemlerle konulur. Tedavi süreci ise semptomatik ajanlar, immünsüpresif ilaçlar ve vakaya göre cerrahi müdahale (timektomi) içeren multidisipliner bir yaklaşım gerektirir.
Juvenile Myasthenia Gravis (JMG) is a rare autoimmune disorder occurring in children under 18, characterized by fluctuating muscle weakness and fatigue caused by autoantibody-mediated blockade of neuromuscular transmission. The disease pathogenesis primarily involves antibodies targeting proteins like acetylcholine receptors (AChR), MuSK, or LRP4, with clinical manifestations ranging from isolated ocular weakness to life-threatening respiratory involvement. Diagnosis is established through clinical assessment, serological antibody testing, and electrophysiological studies. Management requires a multidisciplinary approach incorporating symptomatic treatment, immunosuppressive therapies, and, in specific cases, surgical intervention such as thymectomy.
Referanslar
Willis T. De Anima Brutorum; Oxonii Theatro Sheldoniano: Oxford, UK, 1672.
Patrick, J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science.1973;180: 871–72.
Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570-81.
Yilmaz U, Yis U. Juvenile Myasthenia Gravis: A Report of Three Cases and Literature Review. J. Clin. Anal. Med. 2015;6:473–78
Peragallo JH. Pediatric Myasthenia Gravis. Semin Pediatr Neurol. 2017;24(2):116-21.
O'Connell K, Ramdas S, Palace J. Management of Juvenile Myasthenia Gravis. Front Neurol. 2020;11:743.
Lazaridis K, Tzartos SJ. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol. 2020;11:212.
McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34(3):171-83.
Phillips LH 2nd, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42(10):1888-93.
Zhang X, Yang M, Xu J, Zhang M, Lang B, Wang W, Vincent A. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry. 2007;78(4):386-90.
Castro D, Derisavifard S, Anderson M, Greene M, Iannaccone S. Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscul Dis. 2013;14(3):95-102.
Pineles SL, Avery RA, Moss HE, et al. Visual and systemic outcomes in pediatric ocular myasthenia gravis. Am J Ophthalmol. 2010;150(4):453-59.
Munot P, Robb SA, Niks EH, Palace J, EWSC workshop study group . 242nd ENMC international diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019. Neuromuscul Disord. (2020) 30:254–64.
Popperud TH, Boldingh MI, Brunborg C, et al. Juvenile myasthenia gravis in Norway: A nationwide epidemiological study. Eur J Paediatr Neurol. 2017;21(2):312-17.
Vanikieti K, Lowwongngam K, Padungkiatsagul T, Visudtibhan A, Poonyathalang A. Juvenile Ocular Myasthenia Gravis: Presentation and Outcome of a Large Cohort. Pediatr Neurol. 2018;87:36-41.
Evoli A, Alboini PE, Damato V,et al. Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 2018;1412(1):82-9.
Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011;2011:404101.
Jaretzki A 3rd, Barohn RJ, Ernstoff RM,et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16-23.
Karanfil E, Salcı Y, Fil-Balkan A, Bekircan-Kurt CE, Erdem Özdamar S, Armutlu K. Reliability and Validity of Turkish Myasthenia Gravis-Activities of Daily Living Scale. OTJR (Thorofare N J). 2021;41(2):101-07.
Barnett C, Herbelin L, Dimachkie MM, Barohn RJ. Measuring Clinical Treatment Response in Myasthenia Gravis. Neurol Clin. 2018;36(2):339-53.
Romi F, Hong Y, Gilhus NE. Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol. 2017;49:9-13.
Della Marina A, Trippe H, Lutz S, Schara U. Juvenile myasthenia gravis: recommendations for diagnostic approaches and treatment. Neuropediatrics. 2014;45(2):75-83.
Zhou L, McConville J, Chaudhry V, et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve. 2004;30(1):55-60.
Ricciardi D, Todisco V, Tedeschi G, Cirillo G. Anti-MuSK ocular myasthenia with extrinsic ocular muscle atrophy: a new clinical phenotype? Neurol Sci. 2020;41(1):221-23.
Bacchi S, Kramer P, Chalk C. Autoantibodies to Low-Density Lipoprotein Receptor-Related Protein 4 in Double Seronegative Myasthenia Gravis: A Systematic Review. Can J Neurol Sci. 2018;45(1):62-7.
Rivner MH, Quarles BM, Pan JX,et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study. Muscle Nerve. 2020;62(3):333-43.
Deymeer F, Gungor-Tuncer O, Yilmaz V,et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology. 2007;68(8):609-11.
Koneczny I, Martinez-Martinez P, de Baets M. Myasthenia gravis. In: Ratcliffe MJH (eds). Encyclopedia of Immunobiology. Academic Press,Oxford, UK, 2016;5:168-79.
Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006;16(7):459-67.
Oh SJ, Jeong D, Lee I, Alsharabati M. Repetitive nerve stimulation test in myasthenic crisis. Muscle Nerve. 2019;59(5):544-48.
Padua L, Caliandro P, Di Iasi G, Pazzaglia C, Ciaraffa F, Evoli A. Reliability of SFEMG in diagnosing myasthenia gravis: sensitivity and specificity calculated on 100 prospective cases. Clin Neurophysiol. 2014;125(6):1270-3.
Morren JA, Levin KH, Shields RW. Diagnostic Accuracy of Single Fiber Electromyography for Myasthenia Gravis in Patients Followed Longitudinally. J Clin Neurophysiol. 2016 ;33(5):469-74.
Pascuzzi RM. The edrophonium test. Semin Neurol. 2003;23(1):83-8.
Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16-22.
Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122.
Gilhus NE, Romi F, Hong Y, Skeie GO. Myasthenia gravis and infectious disease. J Neurol. 2018;265(6):1251-58.
Tanovska N, Novotni G, Sazdova-Burneska S, et al. Myasthenia Gravis and Associated Diseases. Open Access Maced J Med Sci. 2018 ;6(3):472-478.
Castro-Suarez S, Guevara-Silva E, Caparó-Zamalloa C, Cortez J, Meza-Vega M. Neuromyelitis optica in patients with myasthenia gravis: Two case-reports. Mult Scler Relat Disord. 2020;43:102173.
Swart J, Giancane G, Horneff G, et al. Paediatric Rheumatology International Trials Organisation (PRINTO), BiKeR and the board of the Swedish Registry. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther. 2018;20(1):285.
Huang X, Liu WB, Men LN,et al. Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci. 2013;34(6):911-17.
Liew WK, Powell CA, Sloan SR, et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol. 2014;71(5):575-80.
Alami Z, Agier MS, Ahid S,et al. Pregnancy outcome following in utero exposure to azathioprine: A French comparative observational study. Therapie. 2018;73(3):199-207.
Weger S, Appendino JP, Clark IH. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab. J Binocul Vis Ocul Motil. 2019;69(1):26-9.
Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr. 2003;143(5):674-7.
Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017-23.
Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36-40.
Madenci AL, Li GZ, Weil BR, Zurakowski D, Kang PB, Weldon CB. The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review. Pediatr Surg Int. 2017;33(6):683-94.
